Literature DB >> 3175838

Incidence of seizures in patients with myelomeningocele: a multifactorial analysis.

W Chadduck1, J Adametz.   

Abstract

To determine the role of ventricular shunts as a cause of seizures in children with hydrocephalus, 190 patients with myelomeningoceles were studied. There was a low incidence of seizures (2%) in the nonshunted patients in spite of a high incidence of ventriculomegaly, whereas the overall frequency of seizures in shunted patients was 22%. Further analysis indicated factors accountable for the increase. Only 9% of patients with shunts that had never required subsequent modification had seizures; however, 22% of the patients had seizures if they had required at least one modification for malfunction alone. Patients with a history of a shunt infection had a further increase in their likelihood of developing seizures to 47%. Information concerning the incidence of seizures by location of the shunt indicated no statistical difference between frontal and parietal entry points, with a frequency of 20% and 26%, respectively; however, there was a higher incidence of seizures in a small group of patients with shunts aberrantly placed in the posterior frontal lobe.

Entities:  

Mesh:

Year:  1988        PMID: 3175838     DOI: 10.1016/0090-3019(88)90300-x

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  12 in total

1.  The Chiari II malformation: cause and impact.

Authors:  David G McLone; Mark S Dias
Journal:  Childs Nerv Syst       Date:  2003-08-12       Impact factor: 1.475

Review 2.  Ventricular shunt infections: immunopathogenesis and clinical management.

Authors:  Yenis Gutierrez-Murgas; Jessica N Snowden
Journal:  J Neuroimmunol       Date:  2014-08-13       Impact factor: 3.478

3.  Comparison of shunt infection incidence in high-risk subgroups receiving antibiotic-impregnated versus standard shunts.

Authors:  Scott L Parker; Frank J Attenello; Daniel M Sciubba; Giannina L Garces-Ambrossi; Edward Ahn; Jon Weingart; Benjamin Carson; George I Jallo
Journal:  Childs Nerv Syst       Date:  2008-11-05       Impact factor: 1.475

4.  Epilepsy in patients with spina bifida in the lumbosacral region.

Authors:  Fumiaki Yoshida; Takato Morioka; Kimiaki Hashiguchi; Tadao Kawamura; Yasushi Miyagi; Shinji Nagata; Futoshi Mihara; Mayu Ohshio; Tomio Sasaki
Journal:  Neurosurg Rev       Date:  2006-08-25       Impact factor: 3.042

5.  Cutibacterium acnes Central Nervous System Catheter Infection Induces Long-Term Changes in the Cerebrospinal Fluid Proteome.

Authors:  Matthew Beaver; Dragana Lagundzin; Ishwor Thapa; Junghyae Lee; Hesham Ali; Tammy Kielian; Gwenn L Skar
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

Review 6.  Shunts vs endoscopic third ventriculostomy in infants: are there different types and/or rates of complications? A review.

Authors:  C Di Rocco; L Massimi; G Tamburrini
Journal:  Childs Nerv Syst       Date:  2006-10-20       Impact factor: 1.475

7.  Gastrointestinal cancer surgery in patients with a prior ventriculoperitoneal shunt: the department of veterans affairs experience.

Authors:  Shilpi Wadhwa; George K Hanna; Andrew R Barina; Riccardo A Audisio; Katherine S Virgo; Frank E Johnson
Journal:  Gastrointest Cancer Res       Date:  2012-07

8.  Observation of continuous spike-waves during slow sleep in children with myelomeningocele.

Authors:  D Battaglia; C Acquafondata; D Lettori; T Tartaglione; V Donvito; S Staccioli; A Mittica; F Guzzetta
Journal:  Childs Nerv Syst       Date:  2004-06-02       Impact factor: 1.475

9.  Outcome of endoscopic third ventriculostomy and Chhabra shunt system in noncommunicating non-tumor childhood hydrocephalus.

Authors:  O E Idowu; L O Falope; A T Idowu
Journal:  J Pediatr Neurosci       Date:  2009-07

10.  Prolonged exposure to antibiotic-impregnated shunt catheters does not increase incidence of late shunt infections.

Authors:  Daniel M Sciubba; Matthew J McGirt; Graeme F Woodworth; Benjamin Carson; George I Jallo
Journal:  Childs Nerv Syst       Date:  2007-03-27       Impact factor: 1.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.